Apremilast as a treatment for psoriasis (Q38019980)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22712800%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

title

Apremilast as a treatment for psoriasis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22712800%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22712800%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

author name string

Brandon Shutty

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22712800%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

Cameron West

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22712800%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

Megan Pellerin

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22712800%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

language of work or name

English

0 references

publication date

20 June 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22712800%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Pharmacotherapy

5 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22712800%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

volume

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22712800%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

issue

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22712800%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

page(s)

1761-1770

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22712800%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

cites work

In the clinic. Psoriasis

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.699959

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.699959

The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: results from NHANES 2003-2004.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.699959

A pharmacoeconomic analysis of severe psoriasis therapy: a review of treatment choices and cost efficiency.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.699959

Psychiatric morbidity in psoriasis: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.699959

The psychosocial impact of psoriasis: physical severity, quality of life, and stigmatization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.699959

An overview and update of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.699959

Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.699959

In touch with psoriasis: topical treatments and current guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.699959

Consensus guidelines for the management of plaque psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.699959

What is new in topical therapy for psoriasis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.699959

Corticosteroids: options in the era of steroid-sparing therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.699959

Molecular mechanisms of tazarotene action in psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.699959

Calcineurin inhibitors and sirolimus: mechanisms of action and applications in dermatology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.699959

Topical corticosteroids in psoriasis: strategies for improving safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.699959

Current investigational drugs in psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.699959

Electronic monitoring of medication adherence in skin disease: results of a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.699959

Interventions to enhance patient adherence to medication prescriptions: scientific review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.699959

Comparison of parent knowledge, therapy utilization and severity of atopic eczema before and after explanation and demonstration of topical therapies by a specialist dermatology nurse

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.699959

Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.699959

10th anniversary Inflammation and Immune Diseases Drug Discovery and Development Summit. 20-21 March 2006, New Brunswick, USA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.699959

An open-label, single-arm pilot study in patients with severe plaque-type psoriasis treated with an oral anti-inflammatory agent, apremilast.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.699959

Disposition, metabolism and mass balance of [14C]apremilast following oral administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.699959

Discovery of (S)-N-[2-[1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl] acetamide (apremilast), a potent and orally active phosphodiesterase 4 and tumor necrosis factor-alpha inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.699959

Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.699959

Keynote review: phosphodiesterase-4 as a therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.699959

PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.699959

Underpinning compartmentalised cAMP signalling through targeted cAMP breakdown

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.699959

cAMP-Specific phosphodiesterase-4 enzymes in the cardiovascular system: a molecular toolbox for generating compartmentalized cAMP signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.699959

Epac: defining a new mechanism for cAMP action

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.699959

The adenosine a2a receptor inhibits matrix-induced inflammation in a novel fashion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.699959

ANP attenuates inflammatory signaling and Rho pathway of lung endothelial permeability induced by LPS and TNFalpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.699959

Prostaglandin E2 suppresses lipopolysaccharide-stimulated IFN-beta production

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.699959

CC-10004 but not thalidomide or lenalidomide inhibits lamina propria mononuclear cell TNF-α and MMP-3 production in patients with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.699959

Apremilast, a novel PDE4 inhibitor, inhibits spontaneous production of tumour necrosis factor-alpha from human rheumatoid synovial cells and ameliorates experimental arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.699959

Modulation of cell proliferation by cytokeratins K10 and K16

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.699959

Two considerations for patients with psoriasis and their clinicians: what defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.699959

Transcriptional profiling after lipid raft disruption in keratinocytes identifies critical mediators of atopic dermatitis pathways.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.699959

Roflumilast: a phosphodiesterase-4 inhibitor for the treatment of severe chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.699959

Exogenous Cushing's syndrome due to topical corticosteroid application: case report and review literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.699959

Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.699959

Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.699959

Methotrexate in psoriasis: a systematic review of treatment modalities, incidence, risk factors and monitoring of liver toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.699959

Oral cyclosporin in psoriasis: a systematic review on treatment modalities, risk of kidney toxicity and evidence for use in non-plaque psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.699959

Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.699959

10.1517/14656566.2012.699959

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22712800%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

1 reference